cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Coherus Biosciences Inc
22 own
14 watching
Current Price
$1.39
$-0.03
(-2.11%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
433.83M
52-Week High
52-Week High
2.97000
52-Week Low
52-Week Low
0.66000003
Average Volume
Average Volume
0.86M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
9.1545
iconMarket Capitalization433.83M
icon52-Week High2.97000
icon52-Week Low0.66000003
iconAverage Volume0.86M
iconDividend Yield--
iconP/E Ratio9.1545
What does the Coherus Biosciences Inc do?
Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company's product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, nonsmall cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behcet's Disease, Crohn's Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Read More
How much money does Coherus Biosciences Inc make?
News & Events about Coherus Biosciences Inc.
Globe Newswire
1 year ago
YUSIMRY (adalimumab-aqvh) product image YUSIMRY (adalimumab-aqvh) - list price $995 per carton of two 40 mg/0.8 mL autoinjectorsSee https://www.yusimry.com for YUSIMRY Full Prescribing Information, including Boxed Warning and Medication guide. $995 per carton (two 40 mg/0.8 mL autoinjectors) ...
Globe Newswire
1 year ago
REDWOOD CITY, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS), today announced that effective June 20, 2023, the compensation committee of the Companys board of directors granted options to purchase an aggregate of 48,000 shares of the ...
Globe Newswire
1 year ago
Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues Acquisition significantly advances Coherus I-O pipeline with anti-IL-27 and anti-CCR8 clinical programs ...
Globe Newswire
1 year ago
Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues Acquisition significantly advances Coherus I-O pipeline with anti-IL-27 and anti-CCR8 clinical programs ...
Globe Newswire
1 year ago
- UDENYCA is the only pegfilgrastim therapy delivered in a convenient, easy-to-administer prefilled autoinjector to offer in-clinic and at-home administration options for cancer patients undergoing myelosuppressive chemotherapy - - An additional presentation, the UDENYCA proprietary on-body injector...
Frequently Asked Questions
Frequently Asked Questions
What is Coherus Biosciences Inc share price today?
plus_minus_icon
Can Indians buy Coherus Biosciences Inc shares?
plus_minus_icon
How can I buy Coherus Biosciences Inc shares from India?
plus_minus_icon
Can Fractional shares of Coherus Biosciences Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Coherus Biosciences Inc stocks?
plus_minus_icon
What is today’s traded volume of Coherus Biosciences Inc?
plus_minus_icon
What is today’s market capitalisation of Coherus Biosciences Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Coherus Biosciences Inc?
plus_minus_icon
What percentage is Coherus Biosciences Inc down from its 52-Week High?
plus_minus_icon
What percentage is Coherus Biosciences Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.39
$-0.03
(-2.11%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Anavex Life Sciences Corp.
Anavex Life Sciences Corp.
$9.21
$-0.94 (-9.26 %)
Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.
$2.08
$0.17 (8.90 %)
Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc.
$1.64
$0.04 (2.50 %)
Nevro Corp
Nevro Corp
$4.57
$0.07 (1.56 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Anavex Life Sciences Corp.
Anavex Life Sciences Corp.
$9.21
$-0.94 (-9.26 %)
Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.
$2.08
$0.17 (8.90 %)
Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc.
$1.64
$0.04 (2.50 %)
Nevro Corp
Nevro Corp
$4.57
$0.07 (1.56 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00